After 35 hours of subcutaneous injection with leronlimab, the patient was detached from high-flow oxygen and he was breathing on his own. Credit: fernando zhiminaicela from Pixabay.

Cytodyn has announced that the first Compassionate Special Permit (CSP) patient in the Philippines treated with a 700mg injection of a CCR5 antagonist, Vyrologix (leronlimab-PRO 140), significantly improved 35 hours after receiving the medication.

An investigational humanised IgG4 mAb8, leronlimab was granted Fast Track designation by the US Food and Drug Administration for two potential indications to treat HIV and metastatic cancer.

Treatment in the patient was carried out under a licenced physician’s request for CSP to treat Covid-19 sufferers.

The patient received high flow oxygen for ten days and was treated with multiple dexamethasone doses, as well as with tocilizumab during this period and failed to show improvement.

After 35 hours of subcutaneous injection with leronlimab, the patient was detached from high-flow oxygen and he was breathing on his own and was discharged from the hospital.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CytoDyn president and CEO Nader Pourhassan said: “We are ready to ship more product for any patients who request leronlimab under CSP in the Philippines.

“I want to reiterate our commitment to the Philippines of at least 100,000 doses upon the FDA Philippines granting Emergency Use Authorization (EUA).

“We believe this anecdotal data and more than 90 approved eINDs (emergency IND) in the US along with the results of our CD12 of 384 mITT (modified intent to treat), double-blinded study that had 82% reduction in 14-day mortality of critically ill, mechanically ventilated patients with statistically significant p-value is a compelling reason to move forward with the EUA request in the Philippines.”

The antibody has so far been studied in 11 clinical trials involving over 1,200 individuals. It has also met primary endpoints in a pivotal Phase III trial of leronlimab plus standard antiretroviral therapies in treatment-experienced HIV patients.